M-CPP and Fenfluramine in Cocaine Addicts - 3

This study has been completed.
Sponsor:
Collaborator:
VA Office of Research and Development
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000314
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: December 2002
  Purpose
The purpose of this study is to evaluate predictive value of M-CPP and fenfluramine challenges for outcome.

Condition Intervention Phase
Cocaine-Related Disorders
Drug: M-CPP
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: To Study Predictive Values of M-CPP and Fenfluramine in Cocaine Addicts

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Hospitalization, arrests, jail, employment, psychiataric symptoms

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   25 Years to 50 Years   (Adult)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000314

Locations
United States, New York
VA Medical Center
Brooklyn, New York, United States, 11209
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
VA Office of Research and Development
Investigators
Principal Investigator: Laure Buydens-Branchey, M.D. VA Office of Research and Development
  More Information

ClinicalTrials.gov Identifier: NCT00000314     History of Changes
Other Study ID Numbers: NIDA-09468-3  R01-09468-3 
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Fenfluramine
1-(3-chlorophenyl)piperazine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Serotonin Uptake Inhibitors
Serotonin Agents
Serotonin Receptor Agonists

ClinicalTrials.gov processed this record on July 28, 2016